Guardant Health, Inc. (GH), a precision oncology company, Monday announced preliminary revenue of $200 million for the fourth quarter, 29 percent higher than the same period a year ago.
On average, 20 analysts expect revenue of $188.92 million for the quarter. Analysts' estimates typically exclude special items.
For the full-year preliminary revenue was $737 million, an increase of 31 percent. The consensus estimate stands at $723.85 million.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.